JDRF & Lilly Canada fund UBC research that could allow people with type 1 diabetes to produce their own insulin
February 07, 2017 11:38 ET
|
JDRF/FRDJ
VANCOUVER, BC--(Marketwired - February 07, 2017) - JDRF and Lilly Canada have awarded a post-doctoral fellowship grant of CAN$60,000 to promising researcher Dr. Cara Ellis, a post-doctoral fellow...
Antidiabetics Market size worth USD 116 Billion by 2023: Global Market Insights Inc.
July 05, 2016 11:00 ET
|
Global Market Insights
Ocean View, Delaware, July 05, 2016 (GLOBE NEWSWIRE) -- Global Antidiabetics Market size is estimated to reach USD 116.1 billion by 2023; as per the latest research report by Global Market...
Helmsley Charitable Trust Awards $2.1 Million to Penn, Stanford and Seattle Children's Research Institute to Explore Cell-Based Therapies for Type 1 Diabetes
April 07, 2016 09:05 ET
|
The Leona M. and Harry B. Helmsley Charitable Trust
NEW YORK, April 7, 2016 (GLOBE NEWSWIRE) -- The Type 1 Diabetes (T1D) Program of The Leona M. and Harry B. Helmsley Charitable Trust has announced $2.1 million in grants to support research toward the...
Helmsley Charitable Trust Awards $3.4 Million to DreaMed Diabetes for Type 1 Diabetes Decision Support
February 03, 2016 16:22 ET
|
The Leona M. and Harry B. Helmsley Charitable Trust
NEW YORK, N.Y., Feb. 3, 2016 (GLOBE NEWSWIRE) -- The Type 1 Diabetes Program of The Leona M. and Harry B. Helmsley Charitable Trust today announced a $3.4 million grant for DreaMed Diabetes (DreaMed)....
PharmaCyte Biotech Has Only Scratched the Surface With Its Cell-in-a-Box(R) Technology
August 17, 2015 09:00 ET
|
PharmaCyte Biotech, Inc.
BONITA, CA--(Marketwired - August 17, 2015) - PharmaCyte Biotech Inc. (OTCQB: PMCB) has made a name for itself with the company’s potentially game-changing pancreatic cancer treatment, and also as the...
PharmaCyte Biotech's Improved Technology Attracting World Class Oncologists
July 30, 2015 09:00 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - July 30, 2015) - PharmaCyte Biotech (OTCQB: PMCB) is a small international biotechnology firm, but you wouldn't know it by the company it keeps. How does PharmaCyte keep...
PharmaCyte Biotech's Cell-in-a-Box Technology Makes Good Cancer Drugs Better
July 13, 2015 09:00 ET
|
PharmaCyte Biotech, Inc.
BONITA, CA--(Marketwired - July 13, 2015) - While many biotech companies are working on new oncology drugs, what's often unappreciated about cancer treatments is how a key improvement in the way drugs...
PharmaCyte Biotech Creates Faster Path to the Clinic for Company's Diabetes Treatment
May 20, 2015 09:30 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - May 20, 2015) - PharmaCyte Biotech (OTCQB: PMCB) has managed to do something that is rarely done in science -- bring together an international group of leading experts to...
Breakthrough Diabetes Research to Be Commercialized by US-Based Nuvilex, Inc.
November 03, 2014 10:49 ET
|
Nuvilex, Inc.
SYDNEY, AUSTRALIA--(Marketwired - November 03, 2014) - Australian research that has produced a line of insulin producing cells that could eliminate the need for injections for Type 1 diabetics will be...
Nuvilex, Inc. Moves Closer to "Bio-Artificial Pancreas" Diabetes Treatment With License for Insulin-Producing Cells
October 21, 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - October 21, 2014) - Nuvilex, Inc. (OTCQB: NVLX) has carefully mapped out its plan to develop a diabetes treatment using the Cell-in-a-Box®
platform technology. It started...